Tumor Necrosis Factor α and Lymphotoxin α Are Not Required for Induction of Acute Experimental Autoimmune Encephalomyelitis by Frei, Karl et al.
 
2177
 
J. Exp. Med. 
 

 
 
 
The Rockefeller University Press • 0022-1007/97/06/2177/06 $2.00
Volume 185, Number 12, June 16, 1997 2177–2182
 
Brief Deﬁnitive Report
 
Tumor Necrosis Factor 
 
 
 
 and Lymphotoxin 
 
 
 
 Are Not
Required for Induction of Acute Experimental
Autoimmune Encephalomyelitis
 
By Karl Frei,
 
*
 
 Hans-Pietro Eugster,
 
‡
 
 Martin Bopst,
 
§
 
Cris S. Constantinescu,
 
 
 
 Ehud Lavi,
 
¶
 
 and Adriano Fontana
 
‡
 
From the 
 
*
 
Department of Neurosurgery and 
 
‡
 
Section of Clinical Immunology, University Hospital 
Zürich, CH-8091 Zürich, Switzerland; 
 
§
 
Swiss Federal Institute of Technology, Institute of Toxicology, 
CH-8603 Schwerzenbach, Switzerland; 
 
 
 
Department of Neurology and 
 
¶
 
Department of Pathology, 
Division of Neuropathology, University of Pennsylvania, Philadelphia, Pennsylvania 19104
 
Summary
 
Immunization of mice with myelin components results in experimental autoimmune encepha-
lomyelitis (EAE), which is mediated by myelin-specific CD4
 
 
 
 T cells and anti-myelin antibod-
ies. Tumor necrosis factor 
 
 
 
 (TNF-
 
 
 
) and lymphotoxin 
 
 
 
 (LT-
 
 
 
) are thought to be involved
in the events leading to inflammatory demyelination in the central nervous system. To ascer-
tain this hypothesis 129 
 
 
 
 C57BL/6 mice with an inactivation of the 
 
tnf
 
 and 
 
lta
 
 genes (129 
 
 
 
C57BL/6
 
 
 
/
 
 
 
) and SJL/J mice derived from backcrosses of the above mentioned mutant mice
(SJL
 
 
 
/
 
 
 
) were immunized with mouse spinal cord homogenate (MSCH) or proteolipid pro-
tein. Both 129 
 
 
 
 C57BL/6
 
 
 
/
 
 
 
 mice and SJL
 
 
 
/
 
 
 
 mice developed EAE. In SJL
 
 
 
/
 
 
 
 mice immu-
nized with MSCH, a very severe form of EAE with weight loss, paralysis of all four limbs, and
lethal outcome was observed. The histologic hallmark was an intense perivascular and paren-
chymal infiltration with predominantly CD4
 
 
 
 T cells and some CD8
 
 
 
 T cells associated with
demyelination in both brain and spinal cord. These results indicate that TNF-
 
 
 
 and LT-
 
 
 
 are
not essential for the development of EAE.
 
E
 
xperimental autoimmune encephalomyelitis (EAE) is a
T cell–mediated inflammatory disease of the central
nervous system (CNS). It is induced in experimental ani-
mals by either active immunization with CNS homogenate,
myelin proteins, or the adoptive transfer of myelin basic
protein (MBP)-specific CD4
 
 
 
 T cell lines. In SJL mice im-
munized with myelin components, the histologic hallmarks
of the disease comprise a perivascular and parenchymal in-
flammation with infiltration of CD4
 
 
 
 T cells, activation of
macrophages and microglial cells, and various degrees of
demyelination. Recent work has suggested that TNF- and
lymphotoxin (LT)-
 
 
 
, also known as TNF-
 
 
 
, may play a
pivotal role in EAE, since both TNF- and LT-
 
 
 
 messenger
RNA and protein have been identified in the CNS in the
acute phase of the disease (1–5). Furthermore, the adminis-
tration of soluble type I receptor of TNF, as well as anti-
bodies to TNF- and LT-
 
 
 
, prevent the development of
EAE in rodents immunized with MBP or injected with en-
cephalitogenic T cells (6–9). The ability of MBP-specific T
cells to transfer the disease was found to be positively cor-
related with the amount of TNF- and/or LT-
 
 
 
 produced
by the T cells (10). TNF-
 
 
 
 is produced in high amounts by
astrocytes from EAE-susceptible Lewis rats, but not from
EAE-resistant Brown-Norway rats (11). Demyelination has
been suggested to be due to the action of TNF- and LT-
 
 
 
because both cytokines mediate oligodendrocyte and mye-
lin damage in vitro (12, 13). Likewise, upon overexpression in
the CNS of transgenic mice, TNF-
 
 
 
 causes demyelination
(14). Furthermore, injections of TNF-
 
 
 
 lead to prolongation
of EAE or can induce relapses in SJL mice that have been
partially or completely recovered from acute EAE (15, 16).
In this study we have investigated the influence of TNF-
and LT-
 
 
 
 on the course of EAE using mice having a simul-
taneous deletion of the 
 
tnf
 
 and 
 
lta
 
 genes (17). Despite previ-
ous evidence for a pathogenetic role of both TNF- and
LT-
 
 
 
 in EAE, we find TNF- and LT-
 
 
 
 double-deficient
mice to be highly susceptible to acute EAE.
 
Materials and Methods
 
Mice.
 
Female SJL/J (H-2
 
s
 
) mice were purchased from Bio-
logical Research Laboratories Ltd. (Füllinsdorf, Switzerland). 129
SV/EV 
 
 
 
 C57BL/6 with inactivated 
 
tnf
 
 and 
 
lta
 
 genes (called 129 
 
 
 
B6
 
 
 
/
 
 
 
, H-2
 
b
 
) have been described recently (17) and were bred
under specific pathogen-free (SPF) conditions. These mice were
backcrossed onto the SJL/J (H-2
 
s
 
) background for six generations
and are called SJL
 
 
 
/
 
 
 
 throughout this paper. Mice homozygous
for inactivation of both the 
 
tnf
 
 and 
 
lta
 
 genes were obtained by in-
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tercrossing heterozygous animals. Homozygous animals were
identified by a diagnostic PCR on genomic DNA described for
the 129 
 
 
 
 B6
 
 
 
/
 
 
 
 mice (17) and a negative PCR result using the
following primer pair: 5
 
 
 
-TCT CAT CAG TTC TAT GGC
CC-3
 
 
 
 and 5
 
 
 
-GGG AGT AGA CAA GGT ACA AC-3
 
 
 
, prov-
ing the lack of the deleted genes. The knockout phenotype was
also ascertained by the lack of lymph nodes and altered splenic
microarchitecture (17). Flow cytometric analysis of splenocytes
showed SJL
 
 
 
/
 
 
 
 mice to be predominantly of the H-2
 
b
 
 haplotype
(FITC anti-mouse H-2D
 
b
 
, clone KH95; PharMingen, San Diego,
CA), and not H-2
 
s
 
 (FITC anti–mouse H-2D
 
s
 
, clone KH43; Phar-
Mingen). Animals were housed under SPF conditions up to 8
wk of age and then transferred to conventional housing where
they were immunized at 10–20 wk of age. Paralyzed animals were
given easy access to food and water.
 
Induction of EAE.
 
Mice were immunized either with mouse
spinal cord homogenate (MSCH; 18) or proteolipid protein (PLP)
peptide in CFA according to a modified method of Brown and
McFarlin (19) and Al-Sabbagh et al. (20), respectively. On day 0,
each mouse received 0.3 ml of a mixture of 5.0 mg MSCH in
0.15 ml PBS (pH 7.4) or 0.2 mg PLP peptide 139-151 (HSLGK-
WLGHPDKF, synthesized by Chiron Technologies, Clayton,
Victoria, Australia) dissolved in 0.15 ml PBS and 0.75 mg of 
 
My
 
-
 
cobacterium tuberculosis
 
, (H37Ra; Difco, Detroit, MI) in 0.15 ml
incomplete Freund’s adjuvant (Difco). The inoculum of 0.3 ml
was injected at 50 
 
 
 
l in each hind footpad and in each of four
spots on the back (two anterior, two posterior, on each side). On
the day of immunization and 2 d later, 10
 
10
 
 heat-inactivated 
 
Bor-
detella pertussis
 
 (Calbiochem Corp., La Jolla, CA) were injected
intraperitoneally in 0.4 ml pertussis diluent (0.015 M Tris, 0.5 M
NaCl, and 0.017% (vol/vol) Triton X-100 in distilled water; ref-
erence 21).
 
Clinical Evaluation of EAE.
 
After the encephalitogenic chal-
lenge, mice were monitored, weighed daily, and disease severity
was scored on a scale of 0 to 5, with 0.5 points for intermediate
clinical findings. The score was designated as follows: 0, no de-
tectable signs of EAE; 1, weakness of the tail; 2, definite tail and
partial hind limb paralysis; 3, complete paralysis of the hind limbs
often associated with incontinence; 4, total paralysis of hind and
forelimbs (mice at grade 4 for 
 
 
 
1 d were euthanized); 5, mori-
bund or death.
 
Histological Analysis.
 
Animals were perfused under anesthesia
through the heart either with Ringer’s solution (for cryosections,
flow cytometry, and reverse transcriptase (RT)-PCR) or with 4%
paraformaldehyde in buffered PBS (for paraffin sections) and spleen,
brain, and spinal cord were dissected out. Paraffin-embedded tis-
sue sections were stained with hematoxylin and eosin and for the
degree of demyelination with Luxol fast blue. Tissue-Tek–embed-
ded sections were stained with anti-CD4 mAb (GK1.5; PharMin-
gen), anti-CD8 mAb (5H10-1; PharMingen), anti-F4/80 mAb
(C1:A3-1; Serotec Ltd., Oxford, U.K.) and corresponding iso-
type-matched primary mAbs. The labeled streptavidin–biotin
technique (DAKO Diagnostics AG, Zug, Switzerland) was cho-
sen for visualization.
 
RT-PCR Analysis for TNF-
 
 
 
, LT-
 
 
 
, IFN-
 
 
 
, and GAPDH.
 
Total RNA was isolated from frozen tissue according to Chom-
czynski and Sacchi (22). 10 
 
 
 
g of total RNA was mixed with 2
 
 
 
g oligo dT primer (Boehringer Mannheim, Rotkreuz, Switzer-
land) in a volume of 10 
 
 
 
l RNase free water and denatured for 5
min at 70
 
 
 
C. Cooling on ice allowed annealing of RT primers.
Reverse transcription was performed in a total volume of 30 
 
 
 
l
containing 6 nmol dNTPs, 0.3 nmol dithiothreitol, 25 units
RNAguard (Pharmacia, Dübendorf, Switzerland) and 100 U
Moloney murine leukemia virus RT (GIBCO, Basel, Switzer-
land) for 4 h at 37
 
 
 
C. The reaction was terminated by incubation
at 95
 
 
 
C for 5 min followed by 5 min at 4
 
 
 
C. The PCR reaction
mix consisted of 2 
 
 
 
l RT reaction mix, 2.5 
 
 
 
l PCR buffer, 2.5
 
 
 
l 12 mM MgCl
 
2
 
, 2 
 
 
 
l 10 
 
 
 
M primer mix, 2.5 
 
 
 
l 2 mM dNTP
mix, and 0.5 units Taq polymerase (0.5 U in 11.4 
 
 
 
l; Appligene,
Oncor, Basel, Switzerland) were added at 55
 
 
 
C after an initial de-
naturation at 95
 
 
 
C for 1 min. A two-step PCR with denaturation
for 15 s at 94
 
 
 
C and annealing for 30 s at 55
 
 
 
C was done for 30 or
35 cycles with a final extension at 72
 
 
 
C for 5 min. PCR products
were visualized in 2% agarose gels containing ethidium bromide.
The following mouse specific primers were used for PCR: TNF-
 
 
 
sense primer, 5
 
 
 
-TCTCATCAGTTCTATGGCCC-3
 
 ; TNF- 
antisense primer, 5 -GGGAGTAGACAAGGTACAAC-3 ; LT- 
sense primer, 5 -CCCATCCACTCCCTCAGAAG-3 ; LT- 
antisense primer, 5 -CGCACTGAGGAGAGGCACAT-3 ; IFN- 
sense primer, 5 -GCTCTGAGACAATGAACGCT-3 ; IFN- 
antisense primer, 5 -AAAGAGATAATCTGGCTCTGC-3 ;
GAPDH sense primer, 5 -CCACCACCCTGTTGCTGTAG-
3 ; GAPDH antisense primer, 5 -CCATCAACGACCCCTTC-
ATT-3 .
Table 1. EAE in TNF and LT- –deficient mice
Genotype
Haplotype
H-2 TNF-  LT-  Age
Immunized
with
Number
sick/total*
Mean day
of onset‡
Mean max.
clinical score§ Mortality
wk %
129   B6 b  /   /  11 MSCH 5/5 14.6   0.9 1.1   0.2 0
129   B6 b  /   /  11 MSCH 5/5 13.8   1.1 1.0   00
SJL/J s  /   /  12–15 MSCH 3/8 15.7   1.5 1.0   00
SJL/J s  /   /  10–12 PLP 8/8 12.3   1.3 2.2   1.2 25
SJL/J b  /   /  15–20 MSCH 8/8 13.0   2.3 3.9   1.6 100
SJL/J b  /   /  12–15 PLP 6/6 16.3   3.7 1.8   1.3 16.7
*Number of animals with clinical signs per total in experiment.
‡Day of onset of clinical signs (mean   SEM).
§Based only on those animals with clinical disease (mean   SEM).2179 Frei et al. Brief Definitive Report
Results and Discussion
Irrespective of whether the tnf and lta genes are inacti-
vated or not, 129   C57BL/6 mice, which had been im-
munized with MSCH, developed a mild form of EAE with
mean clinical scores of 1 (Table 1). The disease started be-
tween days 11 and 17. None of the mice progressed to se-
vere EAE. Histologic analysis revealed a few perivascular
cuffs, predominantly in spinal cord, but no demyelination.
The same clinical and histological picture emerged when
studying SJL/J mice which were immunized with MSCH.
However, when using PLP as the immunogen, SJL/J mice
suffered from a more severe form of EAE, which pro-
gressed to a mean disease score of 2.2   1.2 (Table 1).
Mice with severe disease (clinical score  2) had histologic
evidence for perivascular and parenchymal infiltration of
CD4  T cells and demyelination (data not shown).
To investigate the influence of TNF- and LT-  in the
prototype mouse model of EAE, the TNF- and LT-  dou-
ble-deficient (129   B6 / ) mice were backcrossed into
SJL/J. In these SJL /  mice, the extent of disease was com-
parable when immunized with PLP (Table 1). However,
immunization of SJL /  mice with MSCH resulted in a
dramatic acute form of EAE. Clinically, all eight mice
showed the development of an ascending paralysis affecting
the tail and all four limbs, which uniformly led to death of
the animals. Their weights, which were monitored at daily
intervals, were found to increase from 21.7   2.7 g at the
day of immunization to a maximum of 23.3   2.1 g be-
tween days 9 and 13. Thereafter weight loss was dramatic,
with a 17% decrease at the day of death of the animal
(mean    SEM: 19.4   2.9 g). The development of
cachexia in EAE is a well-established feature and may be
attributed to excessive production of TNF, which has been
named cachectin due to its capability to initiate weight loss
when injected into mice (23). However, the observation of
cachexia in TNF- and LT- –deficient mice with EAE shows
that loss of weight is due to other mechanisms, e.g., dys-
function of brain centers regulating food intake.
Histologic examination of SJL /  mice immunized with
MSCH and a disease score of 3 to 5 showed perivascular
and parenchymal cell infiltrates and demyelination in both
brain and spinal cord. Demyelination was patchy and con-
fined to areas of cell infiltrates. In SJL /  mice with EAE
induced by immunization with PLP, there was only mini-
mal demyelination despite impressive cellular infiltrates. By
immunohistochemistry, the infiltrates were found to con-
sist mainly of CD4  T and some CD8  T lymphocytes
(Fig. 1).
As expected, TNF- and LT-  transcripts as measured by
Figure 1. Histopathologic analysis of spinal cord and brains from TNF- and LT- –deficient mice with acute EAE after immunization with MSCH. (A)
Perivascular infiltrates in spinal cord (longitudinal section, hematoxilin and eosin stain) and (B) demyelination in areas of cell infiltrates in brain tissue
(Luxol fast blue stain). Mononuclear cells in brain tissue consists mainly of CD4  T lymphocytes (C) and CD8  T cells (D) as shown by immunohis-
tochemistry. Staining was performed on 1- m paraffin sections (A and B) or 3- m cryosections (C and D). Original magnifications of A and B, 200; C
and D, 500.2180 EAE in TNF- and LT-  Double-deficient Mice
RT-PCR were absent in brain, spinal cord, and spleen in
the diseased mutant mice (Fig. 2). In agreement with other
reports, the acute phase of EAE in the wild-type controls is
paralleled by expression of both cytokine genes in the CNS
(1–5). No difference was noted when assessing the expres-
sion of the IFN-  gene, which was also detected in the
CNS in TNF- and LT-  knockout mice (Fig. 2). The de-
tection of expression of IFN-  in mice with severe EAE is
of note since evidence is accumulating that IFN-  has a
rather beneficial influence on the disease course. Genetic
inactivation of the IFN-  receptor gene rendered EAE-
resistant mice susceptible (24). Likewise, a more aggressive
disease is observed in IFN-  knockout mice (25, 26).
Our results are remarkable for two reasons. First, it is in-
teresting that TNF- and LT-  deficient mice are able to
generate an autoimmune response to CNS myelin. This
finding was not per se to be expected since TNF- and
LT- –deficient mice not only have an abnormal spleen mi-
croarchitecture, blood lymphocytosis, and absence of lymph
nodes, but also functional alterations (17). These include
defects in T cell–dependent and –independent immune re-
sponses against sheep red blood cells and dinitrophenol-ala-
nyl-glycyl-glycyl-Ficoll, respectively, and a corresponding
lack of germinal center formation (27, 28). In addition the
CTL response to vaccinia virus and lymphocytic chorio-
meningitis virus was found to be reduced (17). Since after
in vivo priming the secondary CTL response to lymphocytic
choriomeningitis virus in vitro was much more pro-
nounced, it has been suggested that in vivo preformed vi-
rus-specific precursor CTL require a prolonged activation
period in vitro to become competent effector cells. On the
humoral site, the SRBC response in TNF- and LT- –defi-
cient mice was reduced for IgM, IgG1, and IgG2b class Igs.
These may be of importance since antimyelin antibodies
led to demyelination in T cell adoptive transfer EAE (29).
However, recent experiments with genetically B cell–defi-
cient mice that were immunized with an MBP encephali-
togenic peptide have shown that B cells are not required
for the activation of encephalitogenic T cells, and hence
the induction of EAE (30).
The data presented here provide evidence that autoim-
munity to myelin can be induced in the absence of TNF-
and LT-  and in the context of the above mentioned
structural and functional deficiencies of the immune system
present in these mutant mice. The second feature of inter-
est from our data is the observation that the autoimmune
response to CNS myelin leads to EAE with CNS inflam-
mation and demyelination. This is in contrast to the expec-
tations which are based on (a) detection of TNF- and LT- 
at the lesion site in EAE, (b) the induction of relapses of
EAE by injection of TNF- , and (c) prevention of EAE by
anti-TNF antibodies or soluble TNF type I receptors (1–
16). The demonstration of CD4  T cells in CNS lesions of
TNF- and LT-  knockout mice with EAE indicates the
generation of sufficient numbers of autoimmune CD4  T
cells, which are able to adhere to CNS endothelium and to
penetrate into the tissue. Thus, these steps, which are re-
quired for induction of EAE, are independent of the action
of TNF- and LT- . Alternatively, in their absence, other
cytokines may compensate for the defect. It is of note that
three other studies did not come to the conclusion that
TNF- and LT-  function as key mediators in EAE. In SJL
and B10.PL mice immunized with synthetic MBP pep-
tides, spinal cord lesions were negative for cells expressing
TNF (31). Furthermore, TNF delivered by using a recom-
binant vaccinia virus system did not enhance, but rather in-
hibited the development of EAE (32). In the same experi-
mental paradigm, anti-TNF antibodies either enhanced,
had no effect or inhibited EAE, depending on the antibody
investigated (21, 32). Thus, the antibodies used in different
studies may show variable cross-reactivity with other im-
munomodulating molecules of the TNF superfamily. In mice
with Theiler’s virus encephalomyelitis, the administration
of rTNF dramatically reduced the extent of demyelination
without influencing the CNS virus titers (33). Rather than
causing demyelination, TNF-  and IFN-  seem to affect
remyelination by inhibition of growth and differentiation
of oligodendrocytes (34).
With the generation of gene knockout mice, a new area
has been opened to study the involvement of distinct gene
products in experimental murine disease models. Studies
using mice carrying an inactivated IFN-  (25, 26) or its re-
ceptor (24) gene have generated results contradicting the
current view on EAE. The same holds true for the TNF-
and LT-  knockout mice presented here. One explanation
for these contradicting results might be that the immune
system of knockout mice becomes biased in a way to favor
compensatory mechanisms leading to the observed out-
come. It is therefore tempting to speculate that conditional
knockout mice, allowing for the temporal and spatial inac-
tivation of a gene (35), might lead to more accurate results
in regard of cytokine-mediated pathogenesis, not only in
EAE, but many other pathologies.
EAE is used as an animal model to study the inflamma-
tory process in multiple sclerosis (MS). TNF- and LT- 
Figure 2. RT-PCR cytokine transcripts from wild type and TNF- and
LT- –deficient mice during acute EAE. Transcripts from different tissues
(br, brain; sc, spinal cord; sp, spleen) from acute EAE induced with PLP or
MSCH from representative mice are shown.2181 Frei et al. Brief Definitive Report
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